New Drug Completes Preclinical Stage, Offers Hope for Rapid Alzheimer's Diagnosis

Oct 18, 2024, 09:18 AM

A new drug developed by specialists from Russian Peter the Great St. Petersburg Polytechnic University aims to protect Alzheimer's patients from memory loss. The drug's main substance, piperazine, is designed to target the brain effectively and has completed the preclinical stage. This development comes amid ongoing efforts to improve dementia diagnosis and treatment. Currently, it takes more than seven years on average to diagnose dementia, but new tests offer hope for rapid diagnosis. Experts are also exploring the potential of 'repurposed' drugs to limit the progression of dementia.